ANI Pharmaceuticals (ANIP) announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the ...

PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets ...

ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of ...

Shares of NASDAQ ANIP opened at $62.49 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 52 week low of $52.50 ...

Christopher Mutz; Senior Vice President, Head of Rare Diseases; ANI Pharmaceuticals Inc Stephen Carey; Chief Financial Officer, Senior Vice President; ANI Pharmaceuticals Inc Good morning everyone.

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full ...

As of March 4, 2025, the average one-year price target for ANI Pharmaceuticals is $80.75/share. The forecasts range from a low of $62.62 to a high of $98.70. The average price target represents an ...

ANI Pharmaceuticals' Q4 adjusted EPS rose to $1.63, beating estimates of $1.44, with sales up 44.8% year-over-year to $190.57 million. 2025 guidance raised: revenue expected at $756M-$776M vs.

Fintel reports that on March 12, 2025, JP Morgan initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Overweight recommendation. As of March 4, 2025, the average one-year price target ...

Good morning, everyone. Welcome to today's ANI Pharmaceuticals Fourth Quarter 2024 Earnings Results Call. Please note, this call is being recorded. After speakers’ remarks there will be a ...